glp-1 drugs pharmaceutical companies news 2025 trends 2025: real-world data, patient outcomes & future therapies Feds, Pharma Companies Strike Deal

52 As previously reported, GLP-1RAs promote antihypertensive effects by enhancing vasodilation through nitric oxide production and modulating the RAAS, reducing plasma angiotensin II levels

Authors contributions Drafting the manuscript, creating figures and tables (WMW), and critically revising the document for important intellectual content (LGL)

Realistic expectations based on ingredient research suggest modest metabolic support rather than pharmaceutical-level weight loss, with effects operating within normal physiological ranges

It is also worth noting that GLP-1RAs are not without complexity in the chronic illness world, especially for patients with EDS or significant gastrointestinal dysmotility

doi: 10.1152/ajpendo.1999.276.6.E1049

doi:10.1210/en.2012-1937 Jin T, Weng J